FDA-cleared profile

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Clinical role
Web-based post-processing, coronary measurement and visualization, automated plaque and stenosis analysis, and structured report preparation for physician review.
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: The software is not intended to replace qualified practitioner judgment and requires trained users. The reported agreement values are table-specific regulatory results, not a product-wide diagnostic sensitivity or clinical-outcome claim.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: DICOM 3.0-compliant CCTA CT images obtained using any CT scanner for CAD or suspected CAD evaluation.
  • Who uses it?Intended users: Trained medical professionals using coronary CT analysis as part of physician diagnostic decision-making.
  • What does the software produce?Output: Coronary-region extraction, suspected stenosis detection, plaque composition overlays, stenosis grading, vessel and lumen volumes, total, calcified, non-calcified and low-density plaque volumes, branch naming, stent and myocardial-bridge detection, and structured reports.
  • What is its most important limitation?Key limitation: The software is not intended to replace qualified practitioner judgment and requires trained users. The reported agreement values are table-specific regulatory results, not a product-wide diagnostic sensitivity or clinical-outcome claim.

Clinical takeaway. Clinical role: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Evidence takeaway. Evidence from the reviewed source record: K251656 FDA evidence is a manufacturer-submitted regulatory agreement package for coronary stenosis and plaque outputs; the stored literature and trial candidate arrays were empty and no independent study was promoted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Web-based post-processing, coronary measurement and visualization, automated plaque and stenosis analysis, and structured report preparation for physician review.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM 3.0-compliant CCTA CT images obtained using any CT scanner for CAD or suspected CAD evaluation.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Coronary-region extraction, suspected stenosis detection, plaque composition overlays, stenosis grading, vessel and lumen volumes, total, calcified, non-calcified and low-density plaque volumes, branch naming, stent and myocardial-bridge detection, and structured reports.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Cardiac CT/CCTA interpretation in cardiology or radiology practice.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Trained medical professionals using coronary CT analysis as part of physician diagnostic decision-making.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software is not intended to replace qualified practitioner judgment and requires trained users. The reported agreement values are table-specific regulatory results, not a product-wide diagnostic sensitivity or clinical-outcome claim.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
K251656 FDA evidence is a manufacturer-submitted regulatory agreement package for coronary stenosis and plaque outputs; the stored literature and trial candidate arrays were empty and no independent study was promoted.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K251656 FDA evidence is a manufacturer-submitted regulatory agreement package for coronary stenosis and plaque outputs; the stored literature and trial candidate arrays were empty and no independent study was promoted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Severe stenosis exact-grade agreement

83.72 percent

  • EndpointExact agreement with labeled severe-stenosis grade
  • PopulationK251656 stenosis-performance measurements labeled severe stenosis
  • Tested versionCareverse CoronaryDoc configuration described in K251656

Non-stenosis exact-grade agreement

98.97 percent

  • EndpointExact agreement with labeled non-stenosis grade
  • PopulationK251656 stenosis-performance measurements labeled non-stenosis
  • Tested versionCareverse CoronaryDoc configuration described in K251656

Total plaque volume PCC

96.94 percent Pearson correlation coefficient

  • EndpointCorrelation of total plaque volume with reference
  • PopulationK251656 plaque-performance measurements
  • Tested versionCareverse CoronaryDoc configuration described in K251656

K251656 Careverse CoronaryDoc stenosis and plaque performance tables

  • DesignRetrospective regulatory agreement testing against labeled/reference measurements across stenosis grades and plaque-volume outputs.
  • PopulationCCTA cardiac CT measurements for CAD or suspected CAD
  • Scopeexact submission
  • Tested versionCareverse CoronaryDoc configuration described in K251656
  • IndependenceSponsor or vendor study

K251656

Measurement counts are reported by grade in the FDA table; unique patient and site counts are not promoted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251656. This does not establish absence of family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-07
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
  • Product family
  • Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251656 or establish individual claim eligibility.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 3.0-compliant CCTA CT images obtained using any CT scanner for CAD or suspected CAD evaluation.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K251656: Careverse CoronaryDoc

  2. Routing

    Source context, not route validation: The FDA summary describes a web application with DICOM CT input, transmission queues, image management, editing, and structured reports; local PACS, RIS, identity, routing, and report-ingestion behavior require testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K251656: Careverse CoronaryDoc

  3. AI processing

    Source context, not route validation: K251656 describes a web-based application; public material reviewed does not establish hosting region, PHI flow, retention, availability, or site-specific service boundaries.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K251656: Careverse CoronaryDoc

  4. Returned objects

    Source context, not route validation: Coronary-region extraction, suspected stenosis detection, plaque composition overlays, stenosis grading, vessel and lumen volumes, total, calcified, non-calcified and low-density plaque volumes, branch naming, stent and myocardial-bridge detection, and structured reports.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K251656: Careverse CoronaryDoc

  5. Viewer/worklist/report

    Unresolved route: Coronary-region extraction, suspected stenosis detection, plaque composition overlays, stenosis grading, vessel and lumen volumes, total, calcified, non-calcified and low-density plaque volumes, branch naming, stent and myocardial-bridge detection, and structured reports.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K251656: Careverse CoronaryDoc

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
K251656 describes a web-based application; public material reviewed does not establish hosting region, PHI flow, retention, availability, or site-specific service boundaries.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The FDA summary describes a web application with DICOM CT input, transmission queues, image management, editing, and structured reports; local PACS, RIS, identity, routing, and report-ingestion behavior require testing.
  • Exact FDA submission
  • Checked 2026-09-07
Training
The exact indication limits use to trained medical professionals who understand the software's functions, capabilities, and limitations.
  • Exact FDA submission
  • Checked 2026-09-07
Monitoring
Monitor eligible CCTA inputs, automated plaque and stenosis edits, report completeness, failed or repeated analyses, PACS/RIS delivery, reader overrides, turnaround, downtime, updates, complaints, and recalls by exact K251656 release.
  • Exact FDA submission
  • Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and limitations.

Web-based coronary analysis

The exact submission is a web-based application for CCTA CT post-processing, coronary measurement, automated plaque and stenosis analysis, and structured reporting.

exact submission · checked 2026-09-07

Digital Heart family context

Careverse lists CoronaryDoc in its Digital Heart family alongside coronary FFR, calcium-score, cardiac-function, and plaque-analysis applications; the page presents family context rather than K251656 release documentation.

product family · checked 2026-09-07

Local interoperability acceptance

Test DICOM import, identity mapping, series selection, routing, structured-report delivery, user roles, edits, and failure recovery with the installed version before clinical use.

exact submission · checked 2026-09-07

This is buyer acceptance guidance based on the FDA-described workflow, not a verified interface contract.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251656
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-09-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No public list price or contract unit for K251656 was established in the reviewed official sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-07 - Exact FDA submission

    The reviewed exact FDA packet and Careverse family page do not establish a current scoped security attestation or deployed data-flow controls.

  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA 510(k) K251656: Careverse CoronaryDoc

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, integration, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Careverse CoronaryDoc (Careverse CoronaryDoc) model card (K251656)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Careverse Digital Doctor Platform: Careverse CoronaryDoc

    Careverse Technology - Accessed 2026-09-07

    Scope: productFamily, clinicalUse, implementationCapabilities, currentCommercialContext

  8. openFDA exact recall query for K251656

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: postmarketSafety

  9. CMS LCD L39913 version 7

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

  10. CMS Article A59813 version 6

    Centers for Medicare & Medicaid Services - Accessed 2026-09-07

    Scope: reimbursementPolicy

Research history

  1. K251656 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K243859

PRAEVAorta®2

Nurea

Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-08-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history